The invalidation of CINVANTI patents is a material negative catalyst. Monitor Heron's appeal to the Federal Circuit — a stay of generic entry pending appeal is possible but not guaranteed. Expect significant downside pressure on HRTX shares as the market prices in generic competition risk.
Price Chart
Executive Summary
The U.S. District Court for the District of Delaware held that the asserted claims of Heron's CINVANTI patents (U.S. Patent Nos. 12,115,255 and 12,290,520) are invalid, removing patent protection for its anti-nausea drug CINVANTI against a generic challenger (Azurity/Slayback). Heron intends to appeal to the Federal Circuit, but the ruling opens the door to near-term generic competition absent a successful appeal or stay.
Key Facts
- District Court held asserted claims of U.S. Patent Nos. 12,115,255 and 12,290,520 invalid on June 1, 2026.
- Ruling covers CINVANTI (aprepitant) injectable emulsion, a key commercial product for Heron.
- Heron intends to appeal to the U.S. Court of Appeals for the Federal Circuit.
- Decision does not affect prior settlement agreements related to CINVANTI or APONVIE.
- No financial figures (revenue, market size, damages) were disclosed in the filing.
Financial Impact
CINVANTI is a commercial product; loss of patent exclusivity threatens material revenue erosion. No specific revenue or market size figures provided in the filing.
Risk Factors
- Generic entry by Azurity/Slayback could begin immediately if no stay is granted, severely impacting CINVANTI sales.
- Appeal to the Federal Circuit may take 12-18 months; outcome uncertain.
- Heron's remaining pipeline and other products may not offset CINVANTI revenue loss.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-253851 |
| Document: hrtx-ex99_1.htm | 0001193125-26-253851 |
| Document: 0001193125-26-253851-index-headers.html | 0001193125-26-253851 |
| Document: 0001193125-26-253851-index.html | 0001193125-26-253851 |
| Document: 0001193125-26-253851.txt | 0001193125-26-253851 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 10, 2026 11w ago | 8-K | $0.3350 | awaiting T+60 | — | $0.3007 (+10.24%) |
Aug 10, 2026 11w ago | Press Release | $0.3350 | awaiting T+60 | — | $0.3007 (+10.24%) |
Jun 25, 2026 17w ago | 8-K | $0.4300 $0.2700 | ▲ +37.21% | ▲ +43.31% | $0.3007 (+30.07%) |
Jun 2, 2026 20w ago | 8-K | $0.4500 $0.3321 | ▲ +26.20% | ▲ +28.70% | $0.3007 (+33.18%) |
May 11, 2026 24w ago | 8-K | $0.9600 $0.5048 | ▲ +47.42% | ▲ +51.81% | $0.3007 (+68.68%) |
May 11, 2026 24w ago | Press Release | $0.9600 $0.5048 | ▲ +47.42% | ▲ +51.81% | $0.3007 (+68.68%) |
Apr 30, 2026 25w ago | DEFA14A | $1.20 $0.4592 | ▼ −61.73% | ▼ −64.84% | $0.3007 (−74.94%) |
Apr 27, 2026 25w ago | Press Release | $1.21 $0.4590 | ▼ −62.07% | ▼ −66.06% | $0.3007 (−75.15%) |
Apr 6, 2026 29w ago | 8-K | $0.8100 $0.4244 | ▼ −47.60% | ▼ −61.07% | $0.3007 (−62.88%) |
Feb 26, 2026 34w ago | 8-K | $1.20 $0.8700 | ▼ −27.50% | ▼ −35.25% | $0.3007 (−74.94%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers